Annexon, Inc. (ANNX:NASDAQ) closed at $3.41 on October 16, 2026, down 5.28% on the day. The stock trades 52.5% below its 52-week high of $7.18 and 34.3% above its 52-week low of $2.54. Over the past year, it gained 8.3%. Annexon, Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -13.89% | -18.23% | -38.78% | -46.97% | +8.25% |
In 252 trading sessions since October 16, 2025, ANNX closed higher on 109 days (43%). Its best day was November 19, 2025 (+26.88%) and its worst was March 12, 2026 (-9.78%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 3 times.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases.
Find more stocks like ANNX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.